Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration.
Familial amyloidotic polyneuropathy (FAP) is an inherited autosomal dominant disease that is commonly caused by accumulation of deposits of transthyretin (TTR) amyloid around peripheral nerves. The only effective treatment for FAP is liver transplantation. However, recent studies on TTR aggregation provide clues to the mechanism of the molecular pathogenesis of FAP and suggest new avenues for therapeutic intervention. It is increasingly recognized that there are common features of a number of protein-misfolding diseases that can lead to neurodegeneration. As for other amyloidogenic proteins, the most toxic forms of aggregated TTR are likely to be the low-molecular-mass diffusible species, and there is increasing evidence that this toxicity is mediated by disturbances in calcium homeostasis. This article reviews what is already known about the mechanism of TTR aggregation in FAP and describes how recent discoveries in other areas of amyloid research, particularly Alzheimer's disease, provide clues to the molecular pathogenesis of FAP.
Hou
Xu
X
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
Aguilar
Marie-Isabel
MI
Small
David H
DH
D000682:Amyloid / Q000096:biosynthesis / Q000378:metabolism; D028227:Amyloid Neuropathies, Familial / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D008954:Models, Biological; D008958:Models, Molecular; D020125:Mutation, Missense; D009417:Nerve Tissue / Q000378:metabolism / Q000473:pathology; D011228:Prealbumin / Q000737:chemistry / Q000502:physiology*
D000682:Amyloid; D011228:Prealbumin